Drug · CHEMBL1200796
Comparisons in its trials686
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
1 to 20 of 686
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| All Patients for Induction, MRD Negative vs All Patients for Induction, MRD Positive: Early Marrow Status (EMS) by MRD Status End Induction (Day 29) | 4,378 of 4,609 | 258 of 362 | 4,971 | NCT00103285 | Trial comparisons |
| Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: deaths from any cause | 205 of 2,400 | 247 of 2,404 | 4,804 | NCT01358877 | Trial comparisons |
| Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: serious adverse events | 792 of 2,364 | 686 of 2,405 | 4,769 | NCT01358877 | Trial comparisons |
Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) vs Docetaxel + Doxorubicin and Cyclophosphamide (TAC): Local, Regional or Metastatic Relapse, or Second Primary Cancer, or Death From Any Cause (Disease-Free Survival) | 356 of 1,649 | 352 of 1,649 | 3,298 | NCT00312208 | Trial comparisons |
| Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) vs Docetaxel + Doxorubicin and Cyclophosphamide (TAC): Death From Any Cause (Overall Survival) | 187 of 1,649 | 202 of 1,649 | 3,298 | NCT00312208 | Trial comparisons |
| Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) vs Docetaxel + Doxorubicin and Cyclophosphamide (TAC): serious adverse events | 331 of 1,634 | 520 of 1,635 | 3,269 | NCT00312208 | Trial comparisons |
| Arm I (Chemotherapy) vs Arm II (Chemotherapy, Trastuzumab): deaths from any cause | 48 of 1,622 | 61 of 1,628 | 3,250 | NCT01275677 | Trial comparisons |
| Arm I (Chemotherapy) vs Arm II (Chemotherapy, Trastuzumab): serious adverse events | 31 of 1,615 | 96 of 1,625 | 3,240 | NCT01275677 | Trial comparisons |
| Adriamycin + Cyclophosphamide vs Fluorouracil + Epirubicin + Cyclophosphamide: serious adverse events | 12 of 1,351 | 26 of 1,337 | 2,688 | NCT00087178 | Trial comparisons |
| Chemotherapy vs Atezolizumab and Chemotherapy: deaths from any cause | 58 of 1,098 | 72 of 1,101 | 2,199 | NCT03498716 | Trial comparisons |
| Chemotherapy vs Atezolizumab and Chemotherapy: Number of Participants With Adverse Events (AE) | 1,074 of 1,084 | 1,090 of 1,093 | 2,177 | NCT03498716 | Trial comparisons |
| Chemotherapy vs Atezolizumab and Chemotherapy: serious adverse events | 173 of 1,084 | 280 of 1,093 | 2,177 | NCT03498716 | Trial comparisons |
| TC Arm vs TAC Arm: deaths from any cause | 110 of 969 | 88 of 965 | 1,934 | NCT00493870 | Trial comparisons |
| TC Arm vs TAC Arm: serious adverse events | 264 of 969 | 330 of 965 | 1,934 | NCT00493870 | Trial comparisons |
| Arm A: FAC vs Arm B: FAC-wP: Overall Survival (OS) Event | 40 of 974 | 31 of 951 | 1,925 | NCT00129389 | Trial comparisons |
| Arm A: FAC vs Arm B: FAC-wP: deaths from any cause | 40 of 974 | 31 of 951 | 1,925 | NCT00129389 | Trial comparisons |
| Arm A: FAC vs Arm B: FAC-wP: Disease-free Survival (DFS) Event | 98 of 974 | 71 of 951 | 1,925 | NCT00129389 | Trial comparisons |
| Arm A: FAC vs Arm B: FAC-wP: serious adverse events | 60 of 974 | 61 of 951 | 1,925 | NCT00129389 | Trial comparisons |
| Tecemotide (L-BLP25) + Cyclophosphamide vs Saline + Placebo: serious adverse events | 303 of 1,024 | 151 of 477 | 1,501 | NCT00409188 | Trial comparisons |
| TAC (Docetaxel) vs FAC (5-fluorouracil): Number of Participants With Disease-Free Survival Events | 287 of 745 | 333 of 746 | 1,491 | NCT00688740 | Trial comparisons |
pipelines-2026-09-18-0.3.1
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1200796/comparisons